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Abstract 33 
Identifying patients who are likely to achieve and maintain a therapeutic INR when prescribed a 34 
vitamin K antagonist (VKA) for stroke prevention in atrial fibrillation (AF) and venous 35 
thromboembolism (VTE) is challenging. The SAMe-TT2R2 score was developed based on common 36 
clinical factors that can highlight patients who may be unable to achieve and maintain good 37 
anticoagulation control and for whom a ‘trial of warfarin’ would be inadvisable. This review 38 
summarises the main published prospective and retrospective studies that have validated the SAMe-39 
TT2R2 score in AF and VTE patients treated with a VKA and how the SAMe-TT2R2 score could aid 40 
clinical decision-making; 19 studies were included. Taken together validation studies suggest that the 41 
SAMe-TT2R2 score is able to predict good or poor anticoagulation control among AF and VTE 42 
patients, although data on VTE patients are limited (3 studies). The available evidence suggests that 43 
the SAMe-TT2R2 score may be a useful tool to aid clinical decision-making for oral anticoagulants 44 
(OAC) in AF and VTE patients. 45 
 46 
Keywords: SAMe-TT2R2 score; atrial fibrillation; venous thromboembolism; vitamin K antagonist; 47 
decision-making; oral anticoagulation 48 
49 
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Introduction 50 
For decades, vitamin K antagonists (VKA, e.g., warfarin) have been the cornerstone of stroke 51 
prevention in atrial fibrillation (AF) and prevention of venous thromboembolism (VTE).
1
 However, 52 
VKA efficacy and safety requires achievement of an international normalised ratio (INR) between 53 
2.0-3.0. Achieving this target INR alone is an inadequate measure of the therapeutic efficacy of 54 
VKA.
1
  55 
 56 
Time in therapeutic range (TTR) is one measure that summarises INR control over time. TTR 57 
is an important and independent predictor of thromboembolic and bleeding outcomes in AF patients 58 
on VKA.
2, 3
 An average individual TTR≥65% is recommended by NICE guidelines,1 while European 59 
guidelines
4
 recommend TTR≥70% to maximize effectiveness and safety of VKAs.  60 
 61 
However, identifying patients who are likely to achieve and maintain a therapeutic INR is 62 
more difficult.  Based on common clinical factors that influence INR and anticoagulation control in 63 
everyday clinical practice, a clinical scoring system, the SAMe-TT2R2 score
5
 (Table 1) was developed 64 
in 2013 to identify risk factors highlighting those patients who may be unable to achieve/maintain 65 
good anticoagulation control and for whom a ‘trial of warfarin’ would be inadvisable. The frequency 66 
of INR measurements are not factored-in (or intended to be). This score assigns 1 point each to female 67 
sex, age <60 years, history of ≥2 co-morbidities (hypertension, diabetes mellitus, coronary artery 68 
disease or myocardial infarction, peripheral artery disease, congestive heart failure, previous stroke, 69 
pulmonary, hepatic, or renal disease) and treatment with drugs interacting with VKA (e.g., 70 
amiodarone) and 2 points each for current/recent tobacco use (within 2-years) and non-white 71 
ethnicity
5 
(Table 1).  The score can be used to aid decision-making by identifying those patients who 72 
would probably do well on VKA (achieving a high TTR, ≥65%) or conversely, those would need 73 
additional interventions to achieve good INR control or to be started on/switched to a non-VKA oral 74 
anticoagulant (NOAC).  The current review summarises studies which have assessed and/or validated 75 
the SAMe-TT2R2 score in patients treated with VKA for AF or VTE.  76 
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 77 
Methods 78 
A comprehensive structured literature search was performed using MEDLINE and EMBASE from 79 
2013 until February 2017; the SAMe-TT2R2 score was first published in 2013. The search strategy 80 
included keywords and MeSH terms relating to AF, deep vein thrombosis, VTE, stroke prevention, 81 
warfarin, VKAs, oral anticoagulant, inception cohort, adverse effect, poor control, INR and SAMe-82 
TT2R2 score (without MeSH term) individually and in combination. Primary published research 83 
articles and abstracts on prospective or retrospective studies validating the SAMe-TT2R2 score were 84 
included. Studies that did not provide comparative outcomes, information on follow-up time, or were 85 
not published in English language were excluded. Manual search of citations was also performed, and 86 
discussion with content experts was undertaken to identify any other relevant studies (Figure 1).  87 
 88 
Results 89 
Searches identified 166 citations.  After removal of duplicates and screening of titles and abstracts, 24 90 
full-text articles were assessed for eligibility and 19 studies were included (see Figure 1). Current 91 
studies assessing the SAMe-TT2R2 score are summarised in Table 2 and baseline patient 92 
characteristics of these cohorts in Table 3. With the exception of three
6-8
 all were performed in AF 93 
patients.
2,5,9-22
 Most studies (n=11)
5-7,11,14,17,19-22
 were performed prospectively, with follow-up duration 94 
ranging from six-months
17
 to 4.7 years.
15 
The number of participants included in VTE cohorts ranged 95 
from 135
6
 to 1943
8
 and between 104
14
 to 8120
21
 in studies on AF patients. 96 
Fourteen studies were performed in European populations,
5-7,9-12,14,17-22
 two in Asian 97 
populations,
15, 16
(with one reporting a target INR 2.0-3.0
15
) and two in North American populations.
8, 98 
13 
Proietti et al
11
 studied a mixed indication clinical trial cohort including patients from Europe, Asia 99 
and Australasia. 100 
Most studies were performed in elderly (mean/median age ranging from 61-76 years) white-101 
Western populations, mainly using warfarin (13 studies)
5-11,13,15,16,19-21
 as the OAC of choice. Most 102 
patients had multiple comorbidities with hypertension the most common, except for the study by Lip 103 
et al
21
 where congestive heart failure was most prevalent. All studies reported a low prevalence of 104 
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smoking status and use of amiodarone for rhythm-control, with the exception of the original 105 
derivation study; 35% of patients used amiodarone.
21
 As the SAMe-TT2R2 score categories increase, 106 
the mean TTR of their study population decreases, except for one study by Domelo-Rodriguez
6 
which 107 
showed the opposite relationship (Figure 2).  108 
Five studies
8,12,13,15,18
 investigated the relationship between components included in the 109 
SAMe-TT2R2 score and TTR. Three studies
12,13,18
 showed that female sex was associated with poor 110 
anticoagulation control; one
18
 showed that having ≥2 comorbidities was related to poor TTR and one13 111 
showed that black ethnicity (as well as NYHA IV) was associated with poorer anticoagulation control. 112 
Chan et al
15
 also reported that having heart failure and diabetes mellitus independently predicts poor 113 
anticoagulation control. 114 
Eight studies
2,5,7-9,12,18, 21
 reported the predictive ability of the SAMe-TT2R2 score using c-115 
statistics (Figure 3). Taken together these validation studies suggest that the SAMe-TT2R2 score is 116 
able to predict good or poor anticoagulation control among AF patients better than chance, with c-117 
statistics ranging from 0.56
12
 to 0.72;
5
 the evidence is less robust in VTE patients (c-statistic 0.52-118 
0.65).
7,8
 119 
Eight studies
11,15,18,20-22
 also examined if the SAMe-TT2R2 score could discriminate AF 120 
patients with clinical events. Five
11,15,18,21,22
 demonstrated some positive associations for SAMe-TT2R2 121 
score predicting clinical events, with c-statistics ranging from 0.55
21
 to 0.62
22 
(Table 4).  Another 122 
study,
8
 also examined if the SAMe-TT2R2 score was associated with clinical outcomes, in particular 123 
recurrent VTE and International Society on Thrombosis and Haemostasis (ISTH) major bleeding rates 124 
in a VTE cohort; patients with a score>2 had more overall adverse event rates (composite of recurrent 125 
VTE and ISTH major bleeding) than those with a score of 0-2 (7.9 vs. 4.5 overall adverse event 126 
rates/100 patient-years respectively).
8
 127 
 128 
Discussion 129 
This review of studies assessing and validating the SAMe-TT2R2 score extends and updates a previous 130 
narrative review
23
 with the addition of validation studies in VTE populations
6, 7
 and validations in 131 
Asian AF populations.
15,16
 Overall, eight studies
2,5,7-9,12,18,21
 suggest that the SAMe-TT2R2 score is able 132 
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to modestly predict quality of anticoagulation control in AF patients receiving VKA therapy, with c-133 
statistics ranging from 0.56
12
 to 0.72.
5 
Many risk scores based on clinical factors such as CHADS2, 134 
CHA2DS2-VASc, Killip and TIMI scores show broadly similar modest c-indexes (approx. 0.6) when 135 
used to predict patients categorised at ‘high risk’ who actually sustain clinical events.24,25 136 
The original purpose of developing the SAMe-TT2R2 score was to produce a simple clinical 137 
schema which could be used routinely in everyday practice to help assess the likelihood of an AF 138 
patient being able to achieve and maintain good anticoagulation control on VKA therapy, using 139 
patient-related clinical parameters which are readily available. The availability of NOACs worldwide 140 
has resulted in increased usage due to their advantages. These include faster onset-of-action (average 141 
maximum effect approximately three hours after intake
26
 compared to VKA (onset 36-72 hours)), 142 
greater reduction in stroke/systemic embolism (+19% compared to VKA
4
), avoidance of INR 143 
monitoring with NOACs,
27
 and absence of achieving/maintaining adequate TTR (as with warfarin). 144 
Achieving a therapeutic INR can take 2-4 weeks and often longer.
3
After termination of study drug in 145 
the NOAC trials, of those patients switching to warfarin, <40% achieved a therapeutic INR within 15 146 
days, and <80% after 30 days;
28
 more strokes occurred during that period in the patients who went 147 
from study drug to VKA than from VKA to VKA.
28,29
 This strongly argues for using NOACs over 148 
VKAs where possible, however, VKAs are still widely used globally and will not disappear from use 149 
especially for AF patients with severe renal impairment, moderate to severe mitral stenosis or 150 
mechanical heart valves.
4
 151 
In addition, in low- and middle-income countries where cost plays an important role in 152 
options available for OAC treatment VKA is still the first-line antithrombotic agent of choice, 153 
therefore the SAMe-TT2R2 score will remain an important decision-making tool, currently and in the 154 
future, to guide physicians choice of anticoagulant treatment.
30
 Most validation studies included in 155 
this review demonstrated good predictive ability except two
6,19
 which demonstrate that the SAME-156 
TT2R2 score was unable to predict anticoagulation control well in their populations. Although both 157 
studies were prospective, results should be interpreted with care as both included small numbers of 158 
participants (135
6
 and 180
19
 respectively) and thus may not be adequately powered to test the 159 
predictive ability of the SAMe-TT2R2 score in regard to anticoagulation control. 160 
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 161 
Importance of good anticoagulation control  162 
Achieving good anticoagulation control (TTR≥65-70%) as recommended by guidelines1,4 is 163 
essential for managing AF and VTE patients treated with VKA. Numerous studies have demonstrated 164 
that a high TTR translates into lower risk of stroke and bleeding.
31-35 
A systematic review 165 
demonstrated that a 7% and 12% improvement in TTR can lead to a reduction in major bleeding and 166 
thromboembolic events, respectively, by 1 event per 100 patient years.
34 
A real-world study
32
 of 167 
27,458 warfarin-treated AF patients (≥3 INR measurements), showed that in patients with good 168 
anticoagulation control (TTR ≥70%), stroke risk was reduced to 79% compared to patients with poor 169 
INR control (TTR ≤30%). However, achieving and maintaining a therapeutic INR can be difficult to 170 
accomplish and therefore, NOACs are preferred to VKA in the majority of patients requiring OAC 171 
initiation.
4
 172 
 173 
 174 
SAMe-TT2R2 score and clinical events 175 
Evident in most studies included in this review,
2,5,7,9-18,20-22
 increasing SAMe-TT2R2 score 176 
demonstrated poorer TTR values which might also translate into poorer clinical outcomes. This can be 177 
evidenced by studies that showed the SAMe-TT2R2 score relating to severe bleeding
22
 and major 178 
bleeding (defined by the Bleeding Academic Research Consortium),
21
 stroke/TE,
21
 adverse 179 
cardiovascular events
22
 and death
21, 22
 during follow-up. In an observational study performed in 911 180 
Spanish AF patients, the SAMe-TT2R2 score also successfully predicted the composite outcome of 181 
major bleeding, TE complications and death.
18
 A Chinese study also demonstrated that a SAMe-182 
TT2R2 score of ≤2 vs. SAMe-TT2R2 of 3 vs. SAMe-TT2R2 ≥4 is associated with lower annual stroke 183 
risk (3.49%/year vs. 4.56% per year vs. 6.41%/year, respectively).
15
 184 
 185 
 186 
Impact of different methods of calculating TTR 187 
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Fauchier and colleagues
36 
 have raised concern about the different methods used to calculate 188 
TTR, whether to use TTR based on the Rosendaal method, percentage of INRs in range (PINRR) 189 
(traditional method) or percentage of visits in range on a given date (cross-sectional method), as these 190 
methods are not interchangeable. In this review, 17 studies
2,5-17,19,20,22 
reported TTR using the 191 
Rosendaal method, only one
18 
calculated time in therapeutic range according to PINRR, while the 192 
other reported ‘labile INR’ as their measure of anticoagulation control.21 Currently there is no 193 
evidence on the optimal method of calculating percentage of INR in range, as each method has its 194 
own unique strengths and weaknesses.
37 
While TTR via the Rosendaal method calculates the exact 195 
percentage of days the INR falls within range, its calculation is more complex than the others and is 196 
based on linear extrapolation. In contrast, calculating TTR via the PINRR method is simpler as it only 197 
looks at the number of INRs that fall within the therapeutic range divided by the total number of INR 198 
tests undertaken. However, the PINNR method does not take into account the actual number of days 199 
of anticoagulant treatment and thus might underestimate control in patients with inconsistent INR 200 
monitoring, patients who have temporarily discontinued therapy and patients with a long gaps 201 
between each INR test, in contrast to the Rosendaal method where these factors will be accounted for, 202 
resulting in a lower TTR. 203 
 204 
Factors affecting anticoagulation control 205 
In this review, only 5 studies
8,12,13,15,18
 investigated the relationship of individual components 206 
of the SAMe-TT2R2 score with the quality of anticoagulation control. Among these female sex
12,13,18
, 207 
>2 comorbidities,
18
 heart failure and diabetes mellitus
15
 (individually) and black ethnicity
5
 were 208 
associated with poor TTR control, however no studies found any association between age <60 years 209 
and smoking with poor TTR. 210 
It is interesting to speculate how some elements of the SAMe-TT2R2 score could influence 211 
anticoagulation control. Some studies
38,39
 investigating predictors of TTR have demonstrated that 212 
women have poorer anticoagulation control compared to men (translating into poorer outcomes), 213 
although the precise mechanism remains unclear.
5
 Similarly, women are known to be at higher risk of 214 
AF-related stroke irrespective of warfarin use.
40,41 
Tobacco use within 2 years scores 2-points in the 215 
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SAMe-TT2R2 score, however most validation studies reported low prevalence of smoking (6.3%-30%) 216 
except in the external validation study by Apostolakis et al
5 
(49% reported as smoker/ex-smoker 217 
(within 2 years)). How smoking can influence anticoagulation control is unclear but it may reflect less 218 
interest in maintaining good health which may translate into poorer adherence to oral anticoagulants, 219 
thus resulting in poor TTR.
5 220 
The original SAMe-TT2R2 score publication suggested that patients who are younger and 221 
have more comorbidities probably have adherence issues with VKA therapy which are reflected by 222 
poor TTR
3
.  In terms of non-white ethnicity, some studies have shown that African-Americans and 223 
Hispanics have poorer anticoagulation control compared to whites and suggest that this may be due to 224 
various reasons including socioeconomic status, poor understanding of therapy, adherence issues, 225 
genetic predisposition, etc.
42,43
 However, these aspects need to be further investigated as studies in 226 
these areas are lacking.  227 
Another editorial
44
 suggests that other factors, not currently within the SAMe-TT2R2 score, 228 
could be included in the assessment of anticoagulation control, such as distance from home to 229 
anticoagulation clinic, which could be the main reason preventing patients attending for regular 230 
follow-up. There is clearly the need for a large prospective randomised trial to evaluate the impact of 231 
SAMe-TT2R2 score-guided therapy with VKA or NOAC not only in relation to anticoagulation 232 
control (TTR) but also towards clinical outcomes (stroke and bleeding), which would formalise its 233 
utility in clinical practice. Hence, where patients have chosen VKA over a NOAC for stroke 234 
prevention or treatment of VTE or where NOACs are contraindicated but a high SAMe-TT2R2 score 235 
(>2) is present, perhaps more frequent follow-up visits and reviews, educational interventions and 236 
counselling
45 
may be required to ensure that INRs are within the therapeutic range in order to achieve 237 
the best outcomes and minimise treatment complications.
 
 238 
 239 
Limitations  240 
The main limitation of the included studies is study design; none utilised a randomised controlled trial 241 
design and most were performed in white populations.  Given that one of the risk factors for poorer 242 
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anticoagulation control is ethnicity, SAMe-TT2R2 score in these populations is automatically worse 243 
compared to non-whites; thus a lower score predicts better control of VKA therapy. Thus, future 244 
studies need to ascertain whether the threshold of the SAMe-TT2R2 score used to indicate probability 245 
of poorer anticoagulation control (SAMe-TT2R2 score ≥2) needs to be modified in non-white 246 
populations so that the SAMe-TT2R2 score is applicable globally. In addition, only three studies have 247 
validated the SAMe-TT2R2 score in VTE cohorts to date, hence more studies are needed specifically 248 
in VTE cohorts to enhance its applicability in these patients. Lastly, only 8 studies reported the c-249 
statistic to quantify the predictive ability of the SAMe-TT2R2 score. 250 
 251 
Conclusions 252 
Making decisions when choosing OAC therapy can be challenging. The available evidence suggests 253 
that the SAMe-TT2R2 score is a useful tool to aid decision-making for OAC in AF (and VTE) patients 254 
and adequately predicts those who are likely to be able/unable to achieve and maintain good INR 255 
control. 256 
257 
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 398 
Table 1: The SAMe-TT2R2 score 399 
 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
†≥2 of the following: hypertension, diabetes mellitus, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive 409 
heart failure, previous stroke, pulmonary, hepatic, or renal disease. 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
 420 
 Component Score 
S Sex (female) 1 
A Age (<60 years) 1 
Me Medical history† 1 
T Treatment (interacting drugs, e.g., amiodarone) 1 
T Tobacco use (within 2-years) 2 
R Race (non-white ethnicity) 2 
 Maximum total score 8 
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Table 2: Studies assessing the SAMe-TT2R2 score in atrial fibrillation and venous thromboembolism cohorts 
 
 
a. Study design 
b. Mean follow-up  
c. Method INR monitoring 
 
Population 
a.  Number 
b.  Mean (SD)/median (IQR) age 
(range, years) 
c.  Race/ethnicity 
d.  OAC used 
SAMe-TT2R2 score distribution  
(%); mean TTR (%) ± SD  
Percentage of patients 
with dichotomised TTR 
(%)  
Pivatto Junior
9
 
2017 
Brazil 
a. Retrospective  
b. 1 year  
c. Hospital OAC clinic 
a. 263 AF 
b. 71.2 (64.1-78.5) 
c. White 
d. 97.3% Warfarin 
0-1: 138 (52.5); 69.2 
≥2: 125 (47.5); 56.3 
- 
Kataruka
8
 
2017 
USA 
a. Retrospective 
b. Median 0.56 years ± 1.13 
c. Hospital OAC clinic 
a. 1943 VTE 
b. 61.8 (15.7) 
c. White 
d. Warfarin  
 
0-1: 665; 57±21 
2: 432; 55±22 
>2: 846; 50±23 
 
TTR<60:57.6 
Bernaitis
16
 
2016 
Singapore  
a. Retrospective  
b. - 
c. Hospital  
a. 1137 AF 
b. 71 (63-77) 
c. Asian 
d. Warfarin  
0-1:0 
2: 339; 63.2±34.1 
>2:798; 55.8±34.1 
- 
Chan
15
 
2016 
Hong Kong 
a.  Retrospective 
b.  4.7 ± 3.6 years 
c.  Hospital  
  
a.  1428 NVAF 
b.  76.2 (8.7) 
c.  Chinese 
d.  Warfarin  
  
2: 22(14.3); 70
†
 
3: 80 (51.9); 70 
4: 41 (26.6); 70 
5: 7 (4.5); 70 
6: 4 (2.6); 70 
TTR≥70: 11 
TTR<70: 89 
  
Demelo-Rodriguez
6
 
2016 
Spain  
a. Prospective  
b. 72,668 patient-years 
c. Primary care 
a. 135 VTE 
b. Median 66
#
 
c. White 
d. Warfarin 
0-1:91; 64.7±19.5 
≥2: 44; 66 ±20.5 
- 
 
Gorzelak-Pabis
14
 
2016 
Poland  
 
a. Prospective  
b. - 
c. Hospital  
 
a. 104 AF with cognitive 
impairment 
b. 75 (10) 
c. White 
d. 61% Acenocoumarol 
 
0-1: 64±26 
≥2: 50±28 
 
- 
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Lip
13
 
2016 
USA 
a. Prospective  
b. 438 days 
c. Trial setting  
a. 229 AF 
b. 66.7 (11) 
c. 80.3% White 
d. Warfarin  
0-1:0.571±0.22 
≥2: 0.498±0.24 
- 
Lobos-Bejarano
12
 
2016 
Spain 
a.  Retrospective 
b.  >12 months  
c.  Primary care  
a.  1524 NVAF 
b.  77.4 (8.7) 
c.  White 
d.  94.8% Acenocoumarol 
0-1: 69.6% ± 17.4 
≥2: 66.6% ± 18.5 
TTR≥65: 60.6 
TTR<65: 39.4 
Palareti
7
 
2016  
Spain 
a.  Prospective  
b.  998 patient-years 
c. Hospital OAC clinic 
a.  1308 VTE 
b.  68(51-78) 
c.  White 
d.  Warfarin  
0-1: 916 (70); 61±22 
≥2:  392 (30); 56±23 
  
TTR≥65: 50.4 
TTR<65: 49.6 
  
Proietti
11
 
2016 
Europe, Asia, Australasia 
a. Prospective  
b. Median 563 days  
c. Trial setting 
a. 3665 AF 
b. 72(66-77) 
c. Mixed‡ 
d. Warfarin  
0-2: 2914 (80.4);  
69.05 (55.63-79.89) 
>2: 710 (19.6);  
66.55 (52.83-77.46) 
TTR>70: 46.9 
TTR≤70: 53.1 
 
Szymanski 
10
 
2016 
Poland 
 
a.  Retrospective 
b.  - 
c.  Hospital 
 
a.  211 AF 
b.  57.1 (10.2) 
c. White 
d. 75.4% warfarin  
 
0-1: 114 (54); 52.3 
≥2: 97 (46); 51.3 
 
TTR>70: 25.2 
TTR≤70: 74.8 
Abumuaileq
18
 
2015 
Spain 
a.  Retrospective  
b.  10 months 
c.  Hospital OAC clinic 
a.  911 NVAF  
b.  73 (11) 
c.  White 
d.  93% Acenocoumarol 
0-1:672 (74); 59±18
¶
 
≥2: 239 (26); 54±19
¶
 
PINRR>65:39 
PINRR≤65:61 
Roldán
44
 
2015  
Spain 
a.  Prospective 
b.  6 months 
c.  Hospital OAC clinic 
a.  459 NVAF 
b.  76 (70-82) 
c.  White 
d.  Acenocoumarol 
<2: 253 (55); 67±18 
≥2: 206 (44.8); 61±16 
TTR>65:54 
TTR≤65:46 
Ruiz-Ortiz
2
 
2015 
Spain 
a.  Retrospective 
b.  Median 27 months  
c.  Cardiology clinic 
a.  1056 NVAF  
b.  73.6 (9.8) 
c.  White 
d.  Acenocoumarol 
0-1:613 (58); 65.6±26.2 
≥2: 443 (42); 61.3±25.3 
TTR≥65:52.7 
TTR≥65:47.3 
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Gallego
22
 
2014 
Spain 
a.  Prospective  
b.  Median 952 days 
c.  Hospital OAC clinic 
a.  972 NVAF  
b.  76 (70-82) 
c.  White 
d.  Acenocoumarol 
0-1:431 (44); 79.67 ±19.46 
≥2: 332 (34); 78.4 ± 20.28 
>2:208 (21); 74.25 ± 20.24 
- 
Lip
21
 
2014 
France 
a.  Prospective 
b.  1016±1018 days 
c.  Clinicians -hospital 
a.  8120 AF 
b.  70 (15) 
c.  White 
d.  Warfarin  
0-1: 4504 (55); 77(1.7)
§
 
≥2: 2252 (28); 52(2.3)
§
 
>2:1364 (17); 43(3.2)
§
 
- 
Poli
20
 
2014 
Italy 
a.    Prospective 
b.   4.6 years 
c.    Hospital OAC clinic 
a.  1089 AF 
b.  75 (30-94) 
c.  White 
d.  Warfarin  
0-1:624 (57); 72.3 ± 15.3 
2: 288 (26); 72.0 ± 15.6 
>2:177 (16); 68.2 ±16.4 
- 
Skov
19
 
2014 
Denmark 
a.  Prospective 
b.  1 year 
c.  Hospital OAC clinic 
a.  182 AF 
b.  70.2
#
 
c.  White 
d.  Warfarin  
0-1:105 (58); 76 
≥2: 77 (42); 76 
- 
Apostolakis
5
 
2013 
United Kingdom 
a.  Retrospective and prospective  
b.  3.5 years 
c. Clinical trial (internal-
validation)/Hospital OAC clinic 
(external-validation) 
 
a.  1305 AF 
b.  69(8)/74(10) 
c.  8.7%, 19.3 % non-white 
(internal/external-validation) 
d.  Warfarin   
(Internal/External validation) 
0: 242 (19); 0.66±0.16/0.7±0.13 
1: 413 (32); 0.65±0.18/0.66±0.17 
2: 303 (23); 0.63±0.17/0.66±0.16 
3:185 (14); 0.59±0.22/0.65±0.17 
Internal validation 
TTR>70:35.7 
TTR≤70:64.3 
External validation 
TTR>70:44.1 
TTR≤70:55.9 
 
AF: atrial fibrillation; CV: cardiovascular; INR: international normalised ratio; IQR: interquartile range; Max: maximum; MI: myocardial infarction; NVAF: non-valvular atrial fibrillation; OAC: oral anticoagulant/anticoagulation; ROC: 
area under curve; SD: standard deviation; SAMe-TT2R2 score: sex (female), age (<60 years, medical history (≥2 of the following: hypertension, diabetes, coronary artery disease or myocardial infarction, peripheral arterial disease, 
congestive heart failure, previous stroke, pulmonary, hepatic, or renal disease), treatment with interacting drugs (e.g. amiodarone[all 1 point],  current tobacco use and race (non-white) [2 points]; TTR: time to therapeutic; TE: 
thromboembolism; VTE: venous thromboembolism 
†TTR presented as ≥70% and <70% not mean TTR; ‡mixed population: White, Black, Asian, other; §number of patients with labile INR, (%); ¶PINRR % (mean ± SD); #no SD or IQR reported;  - not reported
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Table 3: Baseline characteristics of studies assessing SAMe-TT2R2 score in AF and VTE cohorts 
 
 
Patient 
characteristic, N 
(%)  
Sex 
(female) 
Age <60 y Hyperten-
sion 
Diabetes 
mellitus 
Heart 
failure 
Prior 
stroke/TIA  
Peripheral 
arterial 
disease 
Renal 
disease 
Coronary 
artery 
disease 
COPD Current 
smoking 
habit 
Previous 
bleeding  
Treatment: 
Amiodarone 
PivattoJunior9 113 
(43.0) 
41  
(15.6) 
231 
(87.8) 
108 
(41.1) 
149 
(56.7) 
96 
(36.5) 
25 
(9.5) 
7 
(2.7) 
76 
(28.9) 
36 
(13.7) 
37 
(14.1) 
24 
(9.1) 
26 
(9.9) 
Kataruka8 1017  
(52.3) 
1060  
(54.6) 
- - - - - - - - 575 
(29.6) 
- 22  
(1.1) 
Bernaitis16 448 
(39.4) 
172 
(15.1) 
677 
 (59.5) 
343 
(30.2) 
88 
(7.7) 
45 
(4.0) 
- 156 
(13.7) 
271 
(23.8) 
- 84 
(7.4) 
- 78 
(6.9) 
Chan15 671 
(52.5) 
48.0 
(3.4) 
922 
(64.6) 
387 
(27.1) 
367 
(25.7) 
496 
(34.7) 
102 
(7.1) 
2.9 
(2.0) 
407 
(28.5) 
- 71.0 
(5.0) 
- 94 
(6.6) 
Demelo-
Rodriguez6 
(50.4) - (51.9) (18.5) (3.7) (5.2) (3.0) (15.6) - (17.0) (18.5) - - 
Gorzelak-Pabis14 63 
(60.6) 
- 92 
(88.5) 
30 
(28.8) 
72 
(69.2) 
15 
(14.0) 
- - - - 20 
(19.2) 
- 8 
(7.7) 
Lip13 47 
(20.5) 
57 
(24.9) 
206 
(90.0) 
106 
(46.3) 
126 
(55.0) 
26 
(11.4)/ 
14 (6.1) 
31 
(13.5) 
- 178 
(77.7) 
- - - 46 
(20.1)
#
 
L-Bejarano12 741 
(48.6) 
66 
(4.3) 
1223 
(80.2) 
473 
(31.0) 
392.0 
(25.7) 
209.0 
(13.7) 
99 
(6.5) 
92 
(6.0) 
286 
(18.8) 
- 100 
(6.6) 
134 
(8.8) 
100 
(6.6) 
Palareti7 698.0 
(53.4) 
 
446 
(34.1) 
678 
(51.8) 
107 
(8.2) 
36.0 
(2.8) 
66 
(5.0) 
54 
(4.1) 
73 
(5.6) 
99.0 
(7.6) 
- 134 
(10.0) 
- 15 
(1.1) 
Proietti11 1116 
(30.5) 
72§ 
(66-77) 
2812 
(76.7) 
860 
(23.5) 
1372 
(37.4) 
753 
(20.5) 
- - 1619 
(44.2) 
- 334 
(9.1) 
208 
(5.7) 
- 
Szymanski10 79 
(37.4) 
108 
(51.2) 
 27 
(12.8) 
8.0 
(3.8) 
16 
(7.6) 
- - - - 31.0 
(14.7) 
- 17 
(8.1) 
Abumuaileq18 306 
(33.6) 
- 678 
(74.4) 
220 
(24.1) 
343 
(37.7) 
103 
(11.3) 
92 
(10.1) 
36
¶
 
(4) 
127 
(13.9) 
183 
(20.1) 
77 
(8.5) 
115 
(12.6) 
- 
Roldán17 237 
(53.0) 
38 
(8.0) 
368 
(80.0) 
141 
(31.0) 
87 
(19.0) 
67 
(15.0) 
- 51 
(11.0) 
70 
(15.0) 
50 
(11.0) 
38 
(8.0) 
37 
(8.0) 
72 
(16.0) 
Ruiz-Ortiz2 443 
(42.0) 
- 884 
(83.7) 
321 
(30.4) 
235 
(22.2) 
150 
(14.2) 
- 153  
(14.5) 
215 
(20.3) 
176 
(16.7) 
76 
(7.2) 
56 
(5.3)
 ††
 
102 
(9.7) 
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Gallego22 494 
(51.0) 
66 
(7.0) 
796 
(82.0) 
249 
(26.0) 
350 
(36.0) 
182 
(19.0) 
- 94 
(10.0) 
182 
(19.0) 
- 136 
(14.0) 
79 
(8.0) 
- 
Lip21 3,129 
(39) 
- 3,405 
(42.0) 
1,244 
(15.0) 
4,466 
(55.0) 
674 
(8.0) 
- 734 
(9.0) 
2,434 
(30.0) 
870 
(11.0) 
1,053  
(13.0) 
- 1,670 
(35.0) 
Poli20 412 
(37.8) 
61 
(5.6) 
745 
(68.7) 
216 
(19.9) 
268 
(24.7) 
313 
(28.8) 
143 
(13.2) 
- 239 
(22.1) 
- 181  
(16.6) 
- 200 
(18.4) 
Skov19 54 
(29.6) 
23 
(12.6) 
- - - - - - - - 41 
(22.5) 
- 27 
(14.8) 
Apostolakis5
†
 382 
(37.5) 
147 
(14.4) 
692 
(67.9) 
200 
(19.6) 
197 
(19.3) 
130 
(12.8) 
57 
(5.6) 
53 
(5.2)‡ ‡ 
173 
(17.0)
§§
 
- 64.0 
(6.3) 
- 129 
(12.7) 
Apostolakis5‡ 157 
(67.1) 
30.0 
(10.5) 
234 
(81.8) 
64 
(22.4) 
45 
(15.7) 
30.0 
(12.8) 
8 
(2.8) 
2.0 
(0.7)‡ ‡ 
44 
(15.4)
§§
 
- 140 
(49.0) 
- 26 
(9.1) 
 
COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; MI: myocardial infarction; TIA: transient ischemic attack  
†Internal validation; ‡external validation; §median age (IQR); ¶eGFR 30 ml/min/1.73m2; # antiarrhythmic; ††Major bleed; ‡‡ hepatic/renal disease; §§ history of MI 
 24 
 
 
Table 4: Predictive ability (c-statistics) of SAMe-TT2R2 for anticoagulation control and clinical events 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BARC: Bleeding Academic Research Consortium; CV: cardiovascular; INR: international normalised ratio; PINRR: percentage of INR in range; TE: thromboembolism; TTR: time in therapeutic range; - not reported 
 
 Anticoagulation control, c-statistics (95% CI) Clinical events,  c-statistics (95% CI) 
PivattoJunior
9
 TTR≥65: 0.612 (0.544-0.681; p=0.002) - 
Kataruka
8
 TTR<60: 0.61(-) 
TTR<65: 0.65(-) 
TTR<70: 0.65 (-) 
- 
Chan
15
 - Stroke: 0.54 (0.52-0.57)  
Lobos-Bejarano
12
 TTR≥65: 0.562 (0.533-0.592; p<0.001) - 
Palareti
7
 TTR<65: 0.52 (0.48-0.55; p:0.35) - 
Abumuaileq
18
 PINRR ≤70: 0.60 (0.56-0.64; p<0.001) Composite major bleeding, thromboembolic complication or death:  
0.57 (0.51-0.62) 
Ruiz-Ortiz
2
 TTR≥65: 0.57 (0.53-0.60; p<0.0005) - 
Gallego
22
 - Adverse CV event: 0.62 (0.57-0.68; p<0.001)  
Bleeding: 0.55 (0.49-0.62; p=0.117)  
All-cause mortality: 0.62 (0.55-0.68; p<0.001) 
Lip
21
 Labile INR: 0.589 (0.574-0.603) Stroke/TE: 0.561 (0.547-0.575) 
Severe bleeding: 0.552 (0.537-0.566) 
Major BARC bleeding:0. 574 (0.560-0.589)  
Death: 0.544 (0.530-0.559) 
Apostolakis
5
 TTR 31% internal 0.72 (0.64-0.795)  
TTR 36% external 0.70 (0.57-0.82) 
- 
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Figure legends: 
Figure 1: Selection of studies for inclusion – PRISMA flowchart 
Figure 2: Mean TTR vs. SAMe-TT2R2 categories in validation studies 
Legend: SAMe-TT2R2 categories: black= score 0-1; grey= score of 2; white= score >2 
Figure 3: Predictive ability (c-statistics and 95% confidence intervals) of SAMe-TT2R2 and 
anticoagulation control in validation studies  
 
 
 
